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generative disorder worldwide. One major hallmark of PD is
the degeneration of dopaminergic (DA) neurons in the sub-
stantia nigra. Glial cell line-derived neurotrophic factor
(GDNF) potently increases DA neuron survival in models of
PD; however, the underlying mechanisms are incompletely
understood. MicroRNAs (miRNAs) are small, non-coding
RNAs that are important for post-transcriptional regulation
of gene expression. Using small RNA sequencing, we show
that GDNF speciﬁcally increases the expression of miR-182-
5p and miR-183-5p in primary midbrain neurons (PMNs).
Transfection of synthetic miR-182-5p and miR-183-5p mimics
leads to increased neurite outgrowth and mediates neuropro-
tection of DA neurons in vitro and in vivo, mimicking
GDNF effects. This is accompanied by decreased expression
of FOXO3 and FOXO1 transcription factors and increased
PI3K-Akt signaling. Inhibition of endogenous miR-182-5p or
miR-183-5p in GDNF-treated PMNs attenuated the pro-DA
effects of GDNF. These ﬁndings unveil an unknownmiR-medi-
ated mechanism of GDNF action and suggest that targeting
miRNAs is a new therapeutic avenue to PD phenotypes.Received 1 August 2017; accepted 17 January 2018;
https://doi.org/10.1016/j.omtn.2018.01.005.
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Parkinson’s disease (PD) is the second-most-frequent neurodegener-
ative disorder worldwide with a yet-unresolved etiology.1 Although
PD is a system disorder affecting different regions of the brain, the
progressive demise of the nigrostriatal projections and the inability
of this system to regenerate are mainly responsible for the functional
motor deﬁcits observed.2,3 Studies suggest that gene expression regu-
lators might contribute to a large variety of disease states. MicroRNAs
(miRNAs) are endogenous, small, non-coding RNAs that are impor-
tant for the post-transcriptional regulation of gene expression. Since
their discovery, accumulating evidence suggests that they are involved
in the regulation of many developmental programs and biological
processes and are essential for neuronal development and function.4,5
Alterations in miRNA function have been reported in different
neurodegenerative diseases, including PD.6–9 Furthermore, miRNAs
are auspicious therapeutic targets, because the manipulation of theirMolecula
This is an open access article under the CC BY-Nexpression can exert neuroprotection and induce axonal regenera-
tion. However, knowledge on how miRNAs control survival and
axonal regeneration in dopaminergic (DA) neurons is limited. Glial
cell line-derived neurotrophic factor (GDNF) is one of the most
potent pro-DA growth factors that was shown to increase neuronal
survival and regeneration in in vitro and in vivo models of PD.10,11
Here, we analyzed the miRNAome of primary midbrain neurons
(PMNs) by small RNA sequencing to investigate the effects and
mechanism of action of GDNF. Our aim was to identify GDNF-
induced changes in miRNA expression that play a role in mediating
the pro-DA effects of GDNF. We reveal that GDNF increases the
expression of miR-182-5p and miR-183-5p. By employing in vitro
and in vivo approaches, we show that increased levels of these
miRNAs mimic GDNF effects in DA neurons. In addition, we
demonstrate that inhibition of miR-182-5p or miR-183-5p in
GDNF-treated PMN cultures diminishes the beneﬁcial GDNF
effects, suggesting that miR-182-5p and miR-183-5p are involved in
mediating GDNF effects.RESULTS
GDNF Specifically Increases miR-182-5p and miR-183-5p
Expression in PMNs
We employed small RNA sequencing of PMNs treated with vehicle or
GDNF at days in vitro (DIV) 1 or 5 (Figure 1A). As expected, we
observed substantial changes in miRNA expression when comparing
vehicle-treated PMNs at DIV 1 to those at DIV 5 (Figures 1B and 1C).
Speciﬁcally, 122 miRNAs were differentially expressed at the two
developmental stages (Table S1). In contrast, the effect of GDNF treat-
ment on DIV 1 or 5 was more discrete. Only 4 miRNAs were differen-
tially expressed afterGDNF treatment in PMNs atDIV5, among them
miR-182-5p and miR-183-5p, with an increased expression (false dis-
covery rate [FDR] = 0.05, log2 fold change [log2FC] > 0.5) (Figure 1D).r Therapy: Nucleic Acids Vol. 11 June 2018 ª 2018 The Author(s). 9
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. GDNF Increases Expression of miR-182-5p and miR-183-5p in PMNs
(A) Experimental layout for small RNA sequencing. (B) Heatmap showing 122 miRNAs differentially expressed between DIV 1 and DIV 5 (FDR = 0.05, log2FC = 0.5). Arrows
indicate miR-182-5p andmiR-183-5p (n = 5 independent cultures). (C) Volcano plot showing all detectedmiRNAs in DIV 1 and 5 PMNs. Red dots indicate all miRNAs that are
significantly different using only FDR as the cutoff. Green dots indicate all miRNAs that are significantly different using FDR and log2FC as the cutoffs. (D) Upper panel:
heatmap showing the 4 differentially expressed miRNAs (FDR = 0.05, log2FC = 0.5) in vehicle or GDNF-treated PMNs at DIV 5. Lower panel: heatmap showing the
expression of miR-182-5p and miR-183-5p after GDNF treatment at DIV 1. (E) Validation of small RNA sequencing results by qRT-PCR (n = 4 independent cultures).
(F) Expression levels of miR-182-5p and miR-183-5p at DIV 5 in GDNF-treated PMNs after depletion of DA neurons (n = 5 independent cultures). Data are presented as
mean ± SEM and were analyzed by unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001.
Molecular Therapy: Nucleic AcidsWhile using the same cutoff, no differentially expressedmiRNAs were
detected at DIV 1; only miR-182-5p and miR-183-5p showed
a non-signiﬁcant trend for increased expression (Figure 1D).
miR-182-5p and miR-183-5p were also among the 122 differentially
expressed miRNAs when comparing PMNs at DIV 1 to those at
DIV 5 (Figure 1B). Here, miR-182-5p and miR-183-5p decreased at
DIV 5. All these ﬁndings were conﬁrmed by qRT-PCR, showing
that GDNF treatment leads to an upregulation of miR-182-5p and
miR-183-5p and suggesting that thesemiRNAsmay play an important
role in the plasticity of midbrain neurons (Figure 1E). To assess the
question of whether the GDNF-mediated increase in miR-182-5p/
miR-183-5p expression is induced in DA neurons or in the g-amino-
butyric acid (GABA)-ergic PMN population as a secondary effect of
increased GDNF signaling in DA neurons, we chemically depleted
DA neurons by 1-methyl-4-phenylpyridinium (MPP+) and subse-
quently measured miR-182-5p and miR-183-5p expression levels.10 Molecular Therapy: Nucleic Acids Vol. 11 June 2018MPP+ induces a selective DA neuron death in PMN cultures. The
depletion of DA neurons by MPP+ in GDNF-treated PMN cultures
leads to a signiﬁcant decrease in miR-182-5p andmiR-183-5p expres-
sion levels compared to non-toxin-treated controls (Figure 1F). This
ﬁnding indicates that the observed increase of miR-182-5p and
miR-183-5p expression in PMNs after GDNF treatment is induced
in DA neurons. To gain insight into the role of miR-182-5p and
miR-183-5p in midbrain neuron biology, target prediction and func-
tional annotation of the target genes were performed. The results
suggest important roles of GDNF-regulated miR-182-5p and miR-
183-5p in neuronal biology (Table S2).
Increased miR-182-5p and miR-183-5p Levels Mimic GDNF
Effects in DA PMNs
To better understand the role of miR-182-5p and miR-183-5p in DA
neurons, PMN cultures were transfected with synthetic miRNA
Figure 2. Increased miR-182-5p and miR-183-5p Levels Mimic GDNF Effects on Neurites in PMNs
(A) Experimental layout for neurite growth and regeneration experiments. (B and C) Mature miR-182-5p (B) and miR-183-5p (C) levels in PMNs transfected with different
concentrations of the respective mimic 24 hr post-transfection relative to endogenous levels in NC siRNA-transfected PMNs (n = 3 independent cultures). (D) Representative
micrographs of dopaminergic PMNs transfected with NC, the respective miRNA mimics, or NC and treated with GDNF. PMNs were immunostained against tyrosine
hydroxylase (TH) (scale bar, 50 mm). (E) Quantification of the total neurite length per TH+ cell normalized to NC-transfected cultures (n = 3 independent cultures; at least
50 TH+ neurons per culture were analyzed). (F) Right panel: representative micrographs of TH-immunostained and DAPI-counterstainedmiRNAmimic, NC, or GDNF-treated
PMN cultures after mechanical scratch lesion. Left panel: corresponding bright-field images. The scratch border is indicated by the dotted line (scale bar, 10 mm). (G)
Quantification showing the mean length of the 10 longest TH+ neurites crossing the scratch border relative to NC-transfected PMN cultures (n = 3 independent cultures).
Data are presented as mean ± SEM and were analyzed by one-way ANOVA with Dunnett’s post hoc test. ***p < 0.001.
www.moleculartherapy.orgmimics or a scrambled small interfering RNA (siRNA) (negative con-
trol [NC] siRNA) (Figures 2B and 2C), and the effects on neurite
length, regeneration, and survival of DA PMNs were analyzed (Fig-
ures 2, 3A, 3B, 3D, and 3E). Transfection efﬁciency was analyzedby qRT-PCR for three mimic concentrations (Figures 2B and 2C)
and for all subsequent experiments, 5 nM miRNA mimics were
used. For a comparative analysis, PMNs were transfected with NC
siRNA and treated with GDNF in a saturating concentrationMolecular Therapy: Nucleic Acids Vol. 11 June 2018 11
Figure 3. Increased miR-182-5p and miR-183-5p Levels Result in Increased DA Neuron Survival
(A) Experimental layout for MPP+ survival experiments. (B and C) Representative micrographs of PMNs treated with (B) miRNA mimics or GDNF after application of PBS (left
column), 2 mMMPP+ (for 24 hr) (middle column), or 2 mMMPP+ (for 24 hr) and 10 mMLy 294002 (Ly) (for 49 hr, starting 1 hr before MPP+ treatment until the end of experiment)
(right column) and (C) miRNA inhibitors and GDNF after application of PBS (left column) or 2 mMMPP+ (for 24 hr) (right column). PMNs were immunostained against TH (scale
bar, 100 mm). (D) Quantification of TH+ PMNs after transfectionwith miRNAmimics, NC, or treatment with GDNF andwith addition of PBS for 24 hr as an experimental control
(legend continued on next page)
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www.moleculartherapy.org(10 ng/mL). At DIV 4, miR-182-5p- and miR-183-5p-transfected DA
PMNs showed a signiﬁcant increase in neurite length compared to
NC siRNA-transfected cultures, and these effects were of comparable
magnitude to GDNF treatment (Figures 2D and 2E). To analyze the
neuroprotective potential of miR-182-5p and miR-183-5p, the MPP+
neurotoxin model was applied, and DA neuron survival was analyzed
(Figures 3A, 3B, 3D, and 3E). miRNA mimic transfection without
MPP+ treatment did not affect DA cell numbers at DIV 4 (Figure 3D).
After MPP+ treatment, PMNs transfected with miR-182-5p or miR-
183-5p mimics showed a signiﬁcantly higher DA cell survival rate
than did NC siRNA-transfected PMNs (Figure 3E). Again, the neuro-
protective effect was similar to the effect observed after GDNF treat-
ment (Figure 3E). For a more complete picture of the neuroprotective
effects of miR-182-5p andmiR-183-5p onDA neuron survival, PMNs
without toxin treatment were analyzed at DIV 5 and 7, and DA
neuron survival was assessed (Figures S1A and S1B). At DIV 5, no
signiﬁcant increase in DA neuron survival was observed after trans-
fection with miRNA mimics or treatment with GDNF (Figure S1A).
Compared to NC siRNA-transfected PMNs, miR-182-5p mimic- and
miR-182-5p/miR-183-5p mimic-transfected PMNs show signiﬁcant
higher survival of DA neurons at DIV 7. A similar effect on survival
could be observed in GDNF-treated PMNs, but not in miR-183-5p-
transfected tyrosine hydroxylase (TH+) neurons (Figure S1B).
For the assessment of the pro-regenerative potential of miR-182-5p
and miR-183-5p, a mechanical neurite transection was performed
and the length of regenerating DA neurites crossing the scratch
border was quantiﬁed. Compared to NC siRNA, transfection of
miR-182-5p and miR-183-5p mimics signiﬁcantly increased the
length of regenerating neurites, which was comparable in the
GDNF-treated group (Figures 2F and 2G).
To exclude the possibility that the observed effects are unspeciﬁc and
only due to increased miRNA levels per se, all experiments were
repeated transfecting the heart-speciﬁc miR-1a-3p. In previous
studies, miR-1a-3p showed no effect on neurite growth in cortical
neurons.12 Transfection of miR-1a-3p had no effect on neurite
outgrowth, neurite regeneration, or neuroprotection in PMNs (Fig-
ure S2). Thus, the observed ﬁndings represent speciﬁc effects of
miR-182-5p/miR-183-5p transfection.
Inhibition of Endogenous miR-182-5p and miR-183-5p
Diminishes the Effects of GDNF in DA PMNs
To gain deeper insight into the interaction of GDNF and miR-182-5p
and miR-183-5p in DA PMNs, cells were transfected with locked nu-
cleic acid (LNA) miRNA inhibitors after GDNF treatment. As an NC(n = 3 independent cultures). (E) Relative quantification of surviving TH+ PMNs after tran
(for 24 hr) normalized to PBS-treated cells (n = 3 independent cultures). (F) Relative q
treatment with GDNF and addition of 10 mM Ly (for 49 hr) and 2 mMMPP+ (for 24 hr) nor
PMNs after transfection with NC inhibitor, miRNA inhibitor, and/or treatment with GDN
independent cultures). (H) Relative quantification of surviving TH+ PMNs after transfectio
and addition of 2 mMMPP+ for 24 hr normalized to PBS-treated cells (n = 5 independent c
(D and F) with Dunnett’s post hoc test (E, G, and H). **p < 0.01, ***p < 0.001.inhibitor (NC inh) a validated scrambled LNA oligonucleotide was
used, and PMNs treated with GDNF and transfected with NC inh
served as a positive control (Figure 4). To verify the function of the
miRNA inhibitors, we performed western blots against the miRNA
target FOXO1 that is also downregulated upon GDNF treatment.
GDNF treatment and transfection with NC inh led to a signiﬁcant
decrease in FOXO1 protein levels. In contrast, GDNF treatment
and inhibition of miR-182-5p or miR-183-5p restored FOXO1 pro-
tein levels to endogenous levels of GDNF-untreated cells (Figure 4B).
The analyses of DA PMN neurite growth showed that transfection
with NC inh after GDNF treatment led to a signiﬁcant increase in
neurite length compared to NC inh-transfected PMNs without
GDNF treatment. In contrast, transfection of miR-182-5p and miR-
183-5p inhibitors after GDNF treatment diminished the GDNF effect
on neurite length of DA PMNs (Figures 4C and 4D). To assess the ef-
fect of miR-182-5p and miR-183-5p inhibition in GDNF-treated
PMNs on DA neuron survival, the MPP+ model was applied (Figures
3C, 3G, and 3H). In the PBS-treated experimental control, a signiﬁ-
cant increase in DA neuron survival in GDNF-treated, NC inh-
transfected cultures was observed. This effect was decreased in
GDNF-treated PMNs transfected with miR-182-5p and miR-183-
5p inhibitors (Figure 3G). In this context and in these experiments,
GDNF treatment started with the day of culture preparation—
compared to the miRNA mimic experiments, in which the treatment
started 3 hr post-transfection—and a GDNF-mediated increase in DA
PMN survival in PBS-treated cultures was not observed. After MPP+
treatment, NC inh-transfected PMNs treated with GDNF displayed
signiﬁcantly increased DA neuron survival compared to PMN
cultures that were maintained without GDNF. The beneﬁcial effect
of GDNF was decreased in PMNs transfected with miRNA inhibitors
(Figure 3H).
To investigate whether inhibition of miR-182-5p and miR-183-5p
also inﬂuences the GDNF effect on DA PMN neurite regeneration,
a mechanical neurite transection was performed. Although GDNF-
treated cultures show a signiﬁcant increase in DA neurite regenera-
tion, this effect was reduced when miR-182-5p or miR-183-5p was
inhibited (Figures 4E and 4F). These results suggest that miR-182-
5p and miR-183-5p play a role in mediating the beneﬁcial effects of
GDNF on DA PMNs.
miR-182-5p and miR-183-5p Regulate Expression of Foxo
Transcription Factors
For the elucidation of miR-182-5p/miR-183-5p-mediated signaling
mechanisms, we screened the miRTarBase database13 for target genes
that had already been experimentally validated and further analyzedsfection with miRNA mimic, NC, or treatment with GDNF and addition of 2 mMMPP+
uantification of surviving TH+ PMNs after transfection with miRNA mimic, NC, or
malized to PBS-treated cells (n = 5 independent cultures). (G) Quantification of TH+
F (starting at DIV 0) and addition of PBS for 24 hr as an experimental control (n = 5
n with NC inhibitor, miRNA inhibitor, and/or treatment with GDNF (starting at DIV 0)
ultures). Data are presented asmean ±SEMandwere analyzed by one-way ANOVA
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Figure 4. Inhibition of Endogenous miR-182-5p and
miR-183-5p Levels Diminishes GDNF Effects on
Neurites in PMNs
(A) Experimental layout for neurite growth and regenera-
tion experiments. (B) FOXO1 levels in PMNs transfected
with 50 nM of the respective LNA miRNA inhibitor or NC
inhibitor and GDNF treatment 48 hr post-transfection
relative to endogenous levels in NC inhibitor-transfected
PMNs (n = 5 independent cultures). (C) Representative
micrographs of dopaminergic PMNs transfected with NC
inhibitor, the respective miRNA inhibitor, or NC inhibitor
and treated with GDNF. PMNs were immunostained
against tyrosine hydroxylase (TH) (scale bar, 50 mm). (D)
Quantification of the total neurite length per TH+ cell
normalized to NC inhibitor-transfected cultures (n = 5
independent cultures; at least 30 TH+ neurons per culture
were analyzed). (E) Right panel: representative micro-
graphs of TH-immunostained and DAPI-counterstained
PMN cultures treated with miRNA inhibitor, NC, or GDNF
after mechanical scratch lesion. Left panel: corresponding
bright-field images. The scratch border is indicated by the
dotted line (scale bar, 10 mm). (F) Quantification showing
the mean length of the 10 longest TH+ neurites crossing
the scratch border relative to NC inhibitor-transfected
PMN cultures (n = 5 independent cultures). Data are
presented asmean ±SEM andwere analyzed by one-way
ANOVA with Dunnett’s post hoc test. *p < 0.05,
**p < 0.01.
Molecular Therapy: Nucleic Acidsthe FOXO3 and FOXO1 transcription factors. Both have been previ-
ously shown to be targeted by miR-182-5p14,15 and are known to be
involved in the induction of neuronal apoptosis upon oxidative stress
and interference with neurite growth.16–19 FOXO1 is also a predicted
target of miR-183-5p in mice (TargetScan 6.2). Transfection of PMNs
with miR-182-5p mimics was accompanied by a signiﬁcant decrease
in FOXO3 and FOXO1 expression (Figures 5A and 5B). FOXO1 was
also decreased in miR-183-5p-transfected PMNs, validating a previ-
ously predicted miRNA-target gene interaction. In addition,
increased miR-182-5p and miR-183-5p levels resulted in signiﬁcantly
upregulated phosphatidylinositol 3-kinase (PI3K)-Akt signaling,
shown by increased phosphorylated Akt (pAkt) levels, and increased
phosphorylation of S6 (Figures 5C–5E). GDNF increased Akt phos-
phorylation by trend (p = 0.06) and resulted in signiﬁcantly higher
phosphorylation of S6 (Figures 5D and 5E). Increased mitogen-acti-
vated protein kinase (MAPK)-pathway activation was shown for
GDNF-treated PMNs, but not for miR-182-5p and miR-183-5p
mimic-transfected cells (Figure S3). The effect of miRNA increase14 Molecular Therapy: Nucleic Acids Vol. 11 June 2018thus partly mimicked the effects of GDNF treat-
ment, suggesting that miR-182-5p and miR-
183-5p are contributing to the pro-DA effects
mediated by GDNF.
To further investigate the role of FOXO1 and
FOXO3 in DA PMN survival, PMNs were trans-
fected with FOXO1 or FOXO3 siRNA and DA
neuron survival was investigated under theinﬂuence of MPP+ or in untreated cultures compared to NC
siRNA-transfected cultures (Figure S4). siRNA-mediated decrease
in FOXO1 and FOXO3 protein levels resulted in increased DA
neuron survival in PMN cultures treated with PBS or MPP+ (Figures
S4C and S4D), supporting the hypothesis that regulation of FOXO1
and FOXO3 protein levels plays a role in mediating miR-182-5p
and miR-183-5p mimic effects on DA PMNs. In addition, the impor-
tance of PI3K-Akt signaling for mediation of the protective effects of
miR-182-5p and miR-183-5p was addressed by analysis of DA
neuron survival in MPP+-intoxicated PMNs under the inﬂuence of
a speciﬁc inhibitor for PI3K that prevents phosphorylation of Akt,
Ly 294002 (Ly). Inhibition of Akt phosphorylation starting 1 hr
before MPP+ treatment until the end of the experiment diminished
the beneﬁcial effect of miR-182-5p and miR-183-5p on DA neuron
survival in PMN cultures (Figures 3B and 3F).
In conclusion, the observed miRNA effects on neurite outgrowth,
neurite regeneration, and survival of DA neurons appear to be
Figure 5. miR-182-5p/miR-183-5p Regulate Expression of FOXO
Transcription Factors and Activate PI3K-Akt Signaling
(A–E) Western blot analyses for (A) FOXO3 (n = 5 independent experiments [NC +
GDNF, n = 3]), (B) FOXO1 (n = 4 independent experiments [NC + GDNF, n = 3]),
(C) Akt (n = 6 independent experiments [NC + GDNF, n = 3]), (D) pAkt (n = 6
independent experiments [NC + GDNF, n = 3]), and (E) phospho-S6 (pS6)
(n = 5 independent experiments). Data are presented as mean ± SEM and were
analyzed by one-way ANOVA with Dunnett’s post hoc test. *p < 0.05, ***p < 0.001,
xp = 0.06.
www.moleculartherapy.orgmediated by a decrease in FOXO3 and FOXO1 transcription factors
and increased activation of survival signaling via the PI3K-Akt
pathway.
TransfectionwithmiR-182-5p ormiR-183-5p Leads to Increased
Nuclear Translocation of Sp1 in PMNs
To clarify how GDNF, miR-182-5p, and miR-183-5p mediate their
effects and how GDNF regulates the expression of the miRNAs, we
investigated the nuclear levels of the transcription factor Sp1. Sp1
has been previously shown to mediate the expression of miR-182-
5p/miR-183-5p and has putative binding sites in the GDNF
promoter.20–23 There is evidence that activation of the PI3K-Akt
pathway leads to increased transcriptional activity of Sp1.24
PMNs were transfected with miRNA mimics of NC siRNA, and
nuclei were isolated by subcellular fractionation (Figures 6A and
6B). Transfection of PMNs with miR-182-5p or miR-183-5p
resulted in signiﬁcantly increased levels of nuclear Sp1 compared
to PMNs transfected with NC siRNA (Figure 6C). GDNF
treatment of PMNs transfected with the NC siRNA resulted in a
comparable increase in nuclear Sp1 levels (Figure 6C), supporting
the hypothesis that GDNF upregulates miR-182-5p and miR-
183-5p expression by increased nuclear translocation of Sp1
(Figure 6D).
miR-182-5p Mediates Nigrostriatal Protection in the MPTP
Mouse Model of PD
After demonstrating the beneﬁcial effects of GDNF-regulated miR-
182-5p and miR-183-5p on DA neurons in vitro, we investigated the
effect of these miRNAs on DA neurons in the substantia nigra (SN)
in vivo using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) mouse model of PD. First, we demonstrated the successful
transfection of DA neurons in the SN by injection of ﬂuorescently
labeled siRNA (84% ± 1% of TH+ neurons were transfected 48 hr
post-injection) (Figure 7A). Animals received a stereotactic injec-
tion of miR-182-5p/miR-183-5p mimics or NC siRNA into the right
SN and were treated with MPTP for 5 consecutive days (Figures 7D
and 8A). Compared to animals injected with the NC siRNA, nigral
injection of miR-182-5p led to signiﬁcant morphological preserva-
tion of DA cell bodies and, to a lesser extent, their nigrostriatal
projections after MPTP lesion (Figures 7E–7I). This was accompa-
nied by increased striatal dopamine levels in miR-182-5p-injected
animals (Figure 8B), whereas striatal 3,4-dihydroxyphenylacetic
acid (DOPAC) and homovanillic acid (HVA) levels remained
unchanged (Figures 8C and 8D). Injection of miR-183-5p mimics
led to a similar, but not signiﬁcant, trend. Furthermore, theMolecular Therapy: Nucleic Acids Vol. 11 June 2018 15
Figure 6. Increased miR-182-5p or miR-183-5p
Levels Lead to Increased Nuclear Translocation of
Sp1 in PMNs
(A) Experimental layout for subcellular fractionation of
PMNs. (B) Representative western blot analysis of Lamin
B1 as a nuclear envelope marker protein in cytosolic and
nuclear fractions of PMN lysates. (C)Western blot analysis
for Sp1 in nuclear fractions of PMN lysates (n = 4 inde-
pendent experiments). Data are presented as mean ±
SEM and were analyzed by the Kruskal-Wallis test with
the Steel post hoc test. *p < 0.05. (D) Proposed model for
GDNF and miR-182-5p/miR-183-5p interactions and
their effects in PMNs (normal state, left). Without GDNF
treatment or increased miR-182-5p/miR-183-5p levels,
miR-182-5p/miR-183-5p are expressed at basal levels,
inhibiting FOXO1 and FOXO3 translation. Nuclear FOXO
inhibits Sp1 activation, resulting in a limited expression of
GDNF and miR-182-5p/miR-183-5p (proposed model,
right). Binding of GDNF to GDNF family receptor a-1
(GFRA1) leads to an activation of PI3K-Akt signaling,
which in turn leads to activation of growth and survival
pathways and to nuclear import of Sp1, resulting in
increased GDNF and miR-182-5p/miR-183-5p expres-
sion. Increased miR-182-5p/miR-183-5p levels result in
increased translational repression of FOXO and lead
subsequently to activation of Sp1.
Molecular Therapy: Nucleic AcidsMPTP-mediated behavioral deﬁcits in the cylinder test were
partially restored by nigral injection of miR-182-5p or miR-183-
5p (Figure 8E).
DISCUSSION
GDNF25 is one of the most potent pro-DA growth factors, and its
beneﬁcial effects on DA neurons were repeatedly demonstrated in
different in vitro and in vivo models for PD.26 To analyze the effect
of GDNF on the miRNAome of PMNs and to dissect a potential
miRNA-based mode of GDNF action, we performed small RNA
sequencing of RNA isolated from PMNs treated with vehicle or
GDNF at DIV 1 and 5. Our analyses show that GDNF treatment
leads to a speciﬁc upregulation of miR-182-5p and miR-183-5p in
PMNs. In addition, depletion of the DA neuron population in
GDNF-treated PMN cultures results in a signiﬁcant decrease in
miR-182-5p and miR-183-5p, favoring the hypothesis that the
GDNF-dependent increase in miRNA expression is speciﬁcally
induced in DA PMNs. A mutual regulation of neurotrophic factors
and miRNAs has been previously reported,12,27,28 but the ﬁnding
that GDNF regulates the expression of certain neuronal miRNAs
has not been described yet. Brain-derived neurotrophic factor
(BDNF) was shown to induce expression of the miR-212/132 cluster16 Molecular Therapy: Nucleic Acids Vol. 11 June 2018in cortical neurons and retinal ganglion cells
(RGCs),12,27,29 leading to the assumption that
these miRNAs are involved in mediation of
some BDNF effects, because they were known
to play a major role in the regulation of neurite
morphology. This hypothesis was conﬁrmed inRGCs, where the transfection of miR-132 “sponges” abolished the
BDNF effect on neurite branching.29
Because the effect of GDNF on miRNA expression in PMNs was
speciﬁc, we hypothesized that the GDNF-regulated miRNAs might
be involved in mediation of pro-DA GDNF effects. This assumption
was supported by functional annotation of the predicted target genes
for miR-182-5p and miR-183-5p, which suggested an important role
of these miRNAs for neuronal functions. Thus, we analyzed the ef-
fect of increased miR-182-5p and miR-183-5p on DA neurons by
transfecting PMNs with synthetic miRNA mimics or scrambled
NC siRNA. Altogether, the results show that increased levels of
GDNF-regulated miR-182-5p and miR-183-5p lead to increased
neurite length, regeneration, and neuroprotection in DA PMNs
and thus mimic GDNF effects. The observed pro-DA effects are spe-
ciﬁc for miR-182-5p and miR-183-5p, because transfection of miR-
1a-3p mimics did not increase neurite growth or neuronal survival.
Moreover, inhibition of endogenous miR-182-5p or miR-183-5p in
GDNF-treated cultures diminishes the beneﬁcial effects of GDNF
on DA PMNs, supporting the hypothesis that miR-182-5p and
miR-183-5p are involved in mediation of GDNF effects in these
cells. So far, a functional characterization of miR-182-5p and miR-
Figure 7. Effects of Increased miR-182-5p/miR-183-5p Levels on the DA
Nigrostriatal System in the MPTP Mouse Model of PD
(A) Representative micrographs of SN of Alexa Fluor 546 (AF-546)-labeled NC
siRNA-injected animals (left panel, uninjected side; right panel, injected side; scale
bar, 20 mm). (B and C) Relative miR-182-5p (B) and miR-183-5p (C) levels in the
midbrain at indicated time points after injection of miRNA mimics (n = 3 animals per
condition). (D) Experimental layout of in vivo experiments. (E) Exemplary micro-
graphs of the ipsilateral SN. (F) Results of the stereological quantification showing
the numbers of TH+ DA neurons per ipsilateral SN (n = 6 animals per group [PBS,
n = 5]). (G) Stereological quantification of Nissl+ neuronal cells in the ipsilateral SN
(n = 6 animals per group [PBS, n = 5]). (H) Representative micrographs of the
ipsilateral striatum stained for dopamine transporter (DAT). (I) Quantification of DAT+
striatal fiber density relative to PBS control animals (n = 6 animals per group [PBS,
n = 5]). Data are presented as mean ± SEM (C) and were analyzed by one-way
ANOVAwith Dunnett’s post hoc test (F, G, and I). *p < 0.05, **p < 0.01, ***p < 0.001.
www.moleculartherapy.org183-5p in DA neurons has not been published. However, they have
been reported to exert important functions in sensory neurons30 and
memory formation.31 In addition, miR-182-5p and miR-183-5p are
necessary for proper function and maintenance of the retina.32
A study in cortical neurons showed that miR-182-5p regulates neu-
rite outgrowth via activation of the PI3K-Akt pathway.33 Our results
also show increased activation of the PI3K-Akt pathway after in-
crease of miR-182-5p and miR-183-5p in PMNs, and a similar trend
could be observed in NC siRNA-transfected cultures treated with
GDNF. The importance of PI3K-Akt signaling was underlined by
Akt inhibition in MPP+-treated cultures, diminishing the beneﬁcial
effects of both miRNAs and GDNF on DA neuron survival in
PMN cultures.
Similar to GDNF treatment, the increase of both miR-182-5p and
miR-183-5p leads to decreased expression of FOXO1, and increased
miR-182-5p levels resulted in downregulation of the levels of
FOXO3 protein, another member of the FOXO transcription factor
family. By applying siRNA against FOXO1 and FOXO3, the beneﬁcial
effects of decreased FOXO1 and FOXO3 protein levels were
conﬁrmed in DA PMNs, indicating the relevance of the miR-
FOXO1/FOXO3 target pair for the observed results. This is in line
with previous studies reporting that inhibition of FOXO1 and
FOXO3 transcription factors plays a role in neurite growth and regen-
eration, as well as prevention of apoptosis upon oxidative stress in
different models.18,19,34–36 Altogether, these results indicate that the
observed effects of miR-182-5p and miR-183-5p increase in DA
PMNs are at least partially mediated by activation of the PI3K-Akt
signaling pathway and downregulation of FOXO transcription
factors.
Transfection of miR-182-5p and miR-183-5p mimics, as well as
GDNF treatment, leads to increased nuclear translocation of the tran-
scription factor Sp1. The effects of increased nuclear translocation of
Sp1 in DA PMNs have not been described yet, but increased Sp1 acti-
vation has been reported to prevent neuronal death upon oxidative
stress in cortical neurons.37
The results of the PMN study indicated that miR-182-5p and
miR-183-5p exert pro-DA effects and partially mediate the effectsMolecular Therapy: Nucleic Acids Vol. 11 June 2018 17
Figure 8. Effects of Increased miR-182-5p and miR-183-5p Levels on the
Striatal DA Content and Motor Behavior in the MPTP Mouse Model of PD
(A) Experimental layout of in vivo experiments. (B–D) Quantification of striatal DA (B),
3,4-dihydroxyphenylacetic acid (DOPAC) (C), and homovanillic acid (HVA) (D)
contents in the ipsilateral striatum of experimental animals by HPLC (PBS, n = 5
animals; NC, n = 9 animals; miR-182, n = 8 animals; miR-183, n = 9 animals). (E)
Quantification of explorative rearing behavior in the cylinder test showing the pro-
portion of rears the animals performed with the aid of both front paws (both), the left
paw (left), the right (right) paw, or without the use of their front paws (free) (PBS,
n = 5 animals; all other groups, n = 15 animals). Data are presented as mean ± SEM
and were analyzed by one-way ANOVA with Dunnett’s post hoc test. **p < 0.01,
***p < 0.001.
Molecular Therapy: Nucleic Acidsof GDNF in DA PMNs. To verify the validity of these results in vivo,
we studied the effects of increased levels of miR-182-5p and
miR-183-5p in the MPTP mouse model of PD. Compared to NC
siRNA-injected animals, miR-182-5p mimic-injected animals18 Molecular Therapy: Nucleic Acids Vol. 11 June 2018show signiﬁcantly increased survival of DA neurons in the SN,
increased striatal DA ﬁber density, and higher striatal DA content.
miR-183-5p-injected and MPTP-intoxicated animals show a signif-
icant increase in total neuronal cell numbers compared to NC
siRNA-injected mice. These ﬁndings are accompanied by restored
MPTP-induced behavioral deﬁcits in the cylinder test after miR-
182-5p and miR-183-5p mimic injection. The neuroprotective
effects of miR-182-5p mimic injection on SN DA neurons in the
MPTP mouse model are comparable to previously published effects
of nigral GDNF injection.38 The observation that injection of miR-
182-5p and (with limitations) miR-183-5p mimics leads to beneﬁ-
cial effects in the MPTP-mediated DA neuron lesion model
provides further evidence for the neuroprotective effects of these
miRNAs.
This study did not address in detail the mechanism of GDNF-medi-
ated upregulation of miR-182-5p and miR-183-5p expression.
However, a possible explanation for the GDNF-dependent increase
in miR-182-5p and miR-183-5p expression could be the activation
of Sp1, a transcription factor that mediates the expression of miR-
182-5p/miR-183-5p in different cell types and that has putative
binding sites in the GDNF promoter.20–23 Furthermore, it has
been shown that Sp1 can act downstream of the PI3K-Akt
pathway.39–41 In the present study, we show that increased levels
of miR-182-5p and miR-183-5p result in higher activation of the
PI3K-Akt pathway in PMNs. Increased nuclear translocation of
Sp1 after transfection with miR-182-5p or miR-183-5p mimics, as
well as upon treatment with GDNF, has been shown in PMNs.
We hypothesize that this nuclear translocation leads to induction
of SP1-mediated gene expression, which in turn might result in
increased miR-182-5p and miR-183-5p expression upon GDNF
treatment (Figure 5D). Favoring this hypothesis is the ﬁnding
that FOXO1 inhibits the transcriptional capacity of Sp1, as was
shown in hepatocytes.42 Thus, a miR-182-5p/miR-183-5p-mediated
decrease in FOXO1 might lead to increased transcriptional activity
of Sp1.
Our data indicate a potential of miR-182-5p/miR-183-5p for
improving survival and regeneration of DA neurons, which is of
interest for the treatment of PD, even if a more complete assess-
ment of the therapeutic potential of miR-182-5p/miR-183-5p
mimics will require further studies on the mechanism of action
and veriﬁcation in transgenic animal models of PD. The major
challenges in synthetic miRNA-based therapeutics are targeted
cell- or tissue-speciﬁc delivery while preventing the introduction
of supraphysiological miRNA levels. Next to viral vector-based
approaches, possible strategies include conjugation with targeting
molecules or encapsulation to enhance cell-speciﬁc uptake. Similar
to previous attempts to deliver GDNF, microcatheter placement
for local application could also be discussed.43 Our results thus
establish a previously undescribed link between GDNF and miR-
182-5p/miR-183-5p and propose both miRNAs as putative thera-
peutic targets for neurodegenerative disorders with DA demise,
such as PD.
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Cell Culture, Transfection of miRNA Mimics, and Assays for
Neurite Growth and Neuroprotection
PMNs were prepared under serum-free conditions from embryonic
day 12.5 (E12.5) C57BL/6J mice as previously described.44 PMN
cultures used in this study contain on average 6% DA neurons
and 94% GABAergic neurons, with only single glial ﬁbrillary
acidic protein-positive cells being detectable during the culture
time. At DIV 1, PMNs were transfected with synthetic miRNA
mimics (miScript miRNA mimics, QIAGEN, Hilden, Germany)
for mmu-miR-182-5p (50-UUUGGCAAUGGUAGAACUCACA
CCG-30), mmu-miR-183-5p (50-UAUGGCACUGGUAGAAUUC
ACU-30), or mmu-miR-1a-3p (50-UGGAAUGUAAAGAAGUAUG
UAU-30) for dose ﬁnding with 0.1, 5, and 50 nM (all other experi-
ments with 5 nM) using HiPerfect (QIAGEN) as a transfection re-
agent according to manufacturer’s instructions. The latter was used
as a miRNA control to make sure that the observed effects are not a
result of increased miRNA levels per se. As experimental control, we
used a validated scrambled NC siRNA (NC; All Stars Negative
Control siRNA, QIAGEN) that has no homology to any known
mammalian gene. To investigate the effect of inhibition of mmu-
miR-182-5p and mmu-miR-183-5p, DIV 1 PMN cultures were
transfected with 50 nM LNA miRNA inhibitors (miRCURY LNA
Inhibitors, Exiqon, Vedbaek, Denmark) for mmu-miR-182-
5p (miR-182-5p inh; 50-TGTGAGTTCTACCATTGCCAA-30) or
mmu-miR-183-5p (miR-183-5p inh; 50-AGTGAATTCTACCAG
TGCCAT-30) using HiPerfect transfection reagent and a LNA nega-
tive control inhibitor (NC inh; miRCURY LNA Inhibitor Control,
Negative Control A, Exiqon; 50-TAACACGTCTATACGCCCA-30)
as an experimental control. For comparison with the effect of
GDNF treatment, we included an experimental group in which cells
were transfected with NC siRNA/LNA NC inh and treated with
GDNF (PeproTech, Hamburg, Germany) at a ﬁnal concentration
of 10 ng/mL (GDNF treatment starting after the transfection for
mimic experiments and after plating for inhibitor experiments).
For investigation of neuroprotective effects of miR-182-5p/miR-
183-5p, transfected PMNs were treated with 2 mM of MPP+
(Sigma-Aldrich, Taufkirchen, Germany) for 24 hr beginning at
DIV 2. To assess the effect of Akt inhibition on DA PMN survival
after MPP+ treatment, 10 mM of Ly (CST, Leiden, the Netherlands),
a highly speciﬁc inhibitor of PI3K that blocks PI3K-dependent Akt
phosphorylation, was added to the cell culture medium 1 hr before
MPP+ treatment. Ly treatment continued until the end of the exper-
iment (49 hr in total). For assessment of neurite regeneration, a
mechanical transection of neurites was performed at DIV 2. Neurite
growth, regeneration, and survival (after MPP+) of DA TH+ PMNs
were assessed at DIV 4. Survival of DA neurons without toxin was
assessed at DIV 5 and 7.
To investigate the effect of decreased FOXO1 and FOXO3 protein
levels on DA PMN survival, PMNs were transfected with 50 nM of
FOXO1 siRNA (FlexiTube siRNA Mm_FOXO1_4; Mm_FOXO3_2,
QIAGEN) or NC siRNA at DIV 1; subsequently, the MPP+ model
was applied as described earlier.For investigation of DA neurite length, neuronal survival, and neurite
regeneration, PMNs on glass coverslips immunolabeled against TH
were imaged with a Zeiss Axioplan microscope equipped with a
16-bit grayscale charge-coupled device (CCD) camera using the
20 objective and AxioVision SE64 4.9.1 software with the MosaiX
module (Zeiss, Jena, Germany). Per transfection experiment, at least
two independent transfections per culture were performed, and
experiments were replicated at least three times. Per coverslip, two
2.1 mm2 areas (20 images at 20 magniﬁcation) were randomly
imaged and analyzed. All images in one experiment were acquired
with the same exposure time, and for analyses, the same color inten-
sities were used. Images were analyzed using ImageJ 1.48 software
(NIH, Bethesda, Maryland, USA). For analyses of DA neurite length
and regeneration, the NeuronJ macro was applied. For neurite regen-
eration, the 10 longest TH+ neurites along the scratch border per
2.1 mm2 area were analyzed in at least 3 areas per experiment. DA
cell bodies in the MPP+ experiments were counted using the
CellCounter tool.
Small RNA Sequencing, Reverse Transcription, and Real-Time
qPCR
Small RNA sequencing was performed on an Illumina HiSeq 2000
system. Total RNA was isolated from PMNs at different time points
and after GDNF treatment using TRI reagent. Small RNA libraries
were prepared from 1 mg total RNA using the Illumina TruSeq Small
RNA Sample Preparation Kit (San Diego, California, USA). For pro-
cessing of sequencing data, a customized, in-house software pipeline
was used. Quality check and demultiplexing were performed using
the CASAVA 1.8.2 software (Illumina). We trimmed the 30 adapters
and ﬁltered out the reads with the minimum length of 15 nucleotides
using cutadapt. We ﬁrst mapped the reads to the reference genome
created from miRNA sequences. Remaining unmapped reads were
then mapped to the human genome. All mapping was performed
using rna-STAR. We allowed no mismatches for the reads < 25b,
one mismatch for reads between 26b and 33b, two mismatches for
reads between 33b and 59b, and so on. We mapped all reads in the
non-splice-junction-aware mode. For comparison of miRNA expres-
sion between samples, a differential expression analysis was per-
formed using R DESeq2 and the RUVseq package. Small RNA
sequencing data are accessible at GEO: GSE109066. Heatmaps were
created using custom python script for python v.2.7.1 and Matplotlib
1.5.1. Computational miRNA target prediction analysis was per-
formed using TargetScanMouse 6.2.45 Predicted miRNA target genes
were functionally annotated using the data mining environment pro-
vided by the DAVID platform.46 The functional annotation module
was applied for gene ontology terms using an Expression Analysis
Systemic Explorer (EASE) score of 0.1 and a minimum number of
2 counts. Enrichment of miRNA targets in speciﬁc Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) pathways using DIANA
miRPath was employed.47 Already experimentally validated target
genes were searched using the miRTarBase database.13 FOXO1 and
FOXO3 were chosen as miRNA targets for further analyses as follows.
First, experimentally validated targets for mmu-miR-182-5p and
mmu-miR-183-5p were searched using miRTarBase. This resultedMolecular Therapy: Nucleic Acids Vol. 11 June 2018 19
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experimentally validated targets for mmu-miR-183-5p that were
validated with methods giving strong evidence (among them
FOXO3 for miR-182-5p). For comparison, we also looked for exper-
imentally validated targets for hsa-miR-182-5p and hsa-miR-183-5p,
respectively, and found that FOXO1 (for both miRNAs) and FOXO3
(for miR-182-5p) were experimentally validated targets (high evi-
dence). Comparison of these ﬁndings with predicted targets for
mmu-miR-183-5p showed that FOXO1 is also a predicted target
for miR-183-5p in mice. Because FOXO transcription factors are
reported to play an important role in induction of neuronal apoptosis,
we decided to investigate them further as targets for miR-182-5p and
miR-183-5p in our model.
For real-time qPCR, total RNA was isolated from PMNs treated with
vehicle or GDNF at indicated time points. To deplete DA neurons in
the PMN cultures, cells were treated with 5 mM MPP+ for 48 hr
beginning at DIV 3 (RNA isolated at DIV 5). cDNA synthesis from
total RNA was performed using the miScript II RT kit (QIAGEN),
and miRNA expression levels were determined by real-time qPCR
in the CFX96 Touch Real-Time PCR Detection System (Bio-Rad,
Munich, Germany) using the miScript SYBR Green PCR Kit
(QIAGEN) and mature miRNA-speciﬁc primers (Mm_miR-182_2
miScript Primer Assay, Mm_miR-183_1 miScript Primer Assay,
and Mm_miR-1_2 miScript Primer Assay, QIAGEN). miRNA
expression was normalized to the endogenous control RNU6
(Hs_RNU6-2_11 miScript Primer Assay, QIAGEN) in a reaction
volume of 15 mL and under cycling conditions according to manufac-
turer’s instructions.
SDS-PAGE and Immunoblotting
To study the expression levels of miR-182-5p and miR-183-5p targets
FOXO1 and FOXO3, as well as activation of survival- and growth-
associated pathways, western blotting was performed. Protein lysates
were prepared from PMNs 24 hr post-transfection as previously re-
ported.3,48 For investigation of nuclear Sp1 levels, nuclei of PMNs
were isolated by subcellular fractionation as previously reported.49
Western blotting was performed with 20 mg of protein using the
following primary antibodies: monoclonal rabbit anti-FOXO1,
1:500; monoclonal rabbit anti-FOXO3, 1:500; polyclonal rabbit
anti-Akt, 1:1,000; polyclonal rabbit anti-phosphorylated Akt,
1:1,000; and polyclonal rabbit anti-phosphorylated S6 ribosomal
protein (phosphor-S6 [pS6]), 1:1,000 (Cell Signaling Technology,
Cambridge; UK); polyclonal rabbit anti-Sp1 (PEP2), 1:100 (Santa
Cruz Biotechnology, Dallas, Texas, USA); polyclonal rabbit anti-
Lamin B1-nuclear envelope marker, 1:1,000 (Abcam, Cambridge,
UK); monoclonal mouse anti-Gapdh 1:2,000 (HyTest, Turku,
Finland); and monoclonal mouse anti-b-tubulin, 1:5,000 (Sigma-
Aldrich). This was followed by incubation with the corresponding
horseradish peroxidase-coupled secondary antibody (goat anti-rabbit
or goat anti-mouse, 1:2,000; Cell Signaling Technology). For detec-
tion of protein bands, the membrane was incubated with a reagent
for enhanced chemiluminescence for 1 min and either exposed to20 Molecular Therapy: Nucleic Acids Vol. 11 June 2018autoradiography ﬁlms, which were developed in a Curix 60 Devel-
oper, or imaged with a Fusion Pulse 6 imaging system.
Stereotactic Injection of Oligonucleotides and MPTP Treatment
For stereotactic injections of synthetic miRNA mimics into the right
SN of mice, the animals were anesthetized, the scalp was disinfected,
and a longitudinal cut along the midline was executed to expose
bregma and lambda. The coordinates for an injection in the right
SN relative to bregma were set (anterior-posterior [AP], 0.29 cm;
mediolateral [ML], 0.12 cm; dorsal-ventral [DV], 0.45 cm50,51),
and 2 mL of oligonucleotide solution prepared as previously reported8
was injected.
To investigate the neuroprotective effect of increasedmiR-182-5p and
miR-183-5p levels, animals received intraperitoneal injections of
30 mg/kg body weight MPTP or PBS (for controls) on 5 consecutive
days3 beginning 48 hr after the nigral stereotactic injection of the
oligonucleotide. Animals were sacriﬁced at day 14 after the ﬁrst
MPTP injection. All animal experiments were carried out according
to the regulations of the local animal research council and legislation
of the State of Lower Saxony, Germany (G13/1118).
Histology and Neurochemical Analyses
For stereological evaluation of DA neuron numbers in the SN,
midbrain sections were immunostained against TH, followed by a
Nissl staining.3,48 The number of DA (TH+) neurons and the total
number of neurons (Nissl-positive cells) in the ipsilateral SN were
analyzed by counting every 4th 3,3’- diaminobenzidine (DAB)-stained
section over the whole SN using Stereo Investigator software (Micro
Bright Field).
For analysis of striatal ﬁber density, striatal sections were stained
against dopamine transporter (DAT). Every 4th DAT-stained section
over the whole striatum was imaged and analyzed using ImageJ 1.48.
Five sections per animal were analyzed.
For neurochemical analysis of dopamine and its metabolites in the
striatum, homogenates were prepared from fresh, unﬁxed tissue.
Striatal dopamine, DOPAC, and HVA were quantiﬁed by high-per-
formance liquid chromatography (HPLC) as previously reported.3,48
Analysis of Rearing Behavior
To evaluate potential changes in motor behavior after miRNA mimic
injection in the MPTP mouse model, forelimb use during natural
exploratory behavior was assessed using the cylinder rearing test.52
Statistical Analysis
Statistical analysis was performed with KyPlot v.2.0 (KyensLab) and
SigmaPlot v.11 (Systat Software). Data are given as mean ± SEM.
The statistical test and the number of experiments or animals used
for analysis are indicated in the respective ﬁgure legends. No data
points were removed from statistical analyses. In all experiments,
no statistical methods were used to predetermine sample sizes, but
sample sizes are similar to those routinely used in the ﬁeld for these
www.moleculartherapy.orgexperiments. Differences were considered signiﬁcant with p < 0.05
(*p < 0.05, **p < 0.01, ***p < 0.001).
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Supplemental information 
 
Supplemental figures 
 
 
 
Figure S1 – Effects on DA neuron survival at DIV 5 and DIV 7 (Corresponding to Fig 3). 
A+B Relative quantification of surviving TH+ PMNs after transfection with miR mimic, NC or treatment with 
GDNF at DIV 5 (A) and DIV 7 (B) normalized to NC (n = 3-5) independent experiments). Data are presented as 
mean ± SEM and were analyzed by one way ANOVA with Dunnett’s post-hoc test. * P < 0.05, ** P < 0.01. 
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Figure S2 – Effects on neuronal survival and neurite growth are not caused by an increase in miRNA 
levels per se (Corresponding to Fig 2+3). 
A Experimental layout for miR-1a-3p experiments. 
B Relative miR-1a-3p level in cultures transfected with miR-1a-3p mimic normalized to NC transfected cultures 
(n = 3 independent cultures).  
C Quantification of neurite length of dopaminergic PMNs transfected with miR-1a-3p mimic or NC (n = 3 
independent cultures).  
D Quantification of TH+ PMNs after transfection with miR-1a-3p mimics or NC and with addition of PBS for 
24 h as experimental control.  
E Relative quantification of surviving TH+ PMNs after transfection with miR-1a-3p mimics or MC and addition 
of 2 µM MPP+ for 24 h normalized to PBS treated cells (n = 3 independent cultures).  
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F Quantification of total length of TH+ neurites growing over the scratch border relative to NC transfected 
PMNs (n = 3 independent cultures).  
G Quantification showing the mean length of the 10 longest TH+ neurites crossing the scratch border relative to 
NC transfected cultures (n = 3 independent cultures). Data are given as mean ± SEM and analyzed by one-way 
ANOVA. 
 
 
 
Figure S3 – Effects of miR-182-5p and miR-183-5p increase and GDNF treatment on MAPK signaling in 
PMNs (Corresponding to Fig 5). 
A+B Western blot analyses for A Erk1 and Erk2 (n = 4 independent experiments) and B pErk1 (left; n = 4 
independent experiments) and pErk2 (right; n = 4 independent experiments. Data are presented as mean ± SEM 
and were analyzed by one way ANOVA with Dunnett’s post-hoc test. * P < 0.05. 
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Figure S4 – Decrease in FOXO1 and FOXO3 levels lead to a higher DA neuron survival in PMN cultures 
(Corresponding to Fig 5). 
A+B Relative FOXO1 (left) and FOXO3 (right) protein levels in PMN cultures transfected with Foxo1 and/ or 
Foxo3 siRNA normalized to NC transfected cultures (n = 5 independent cultures). Data are presented as mean ± 
SEM and were analyzed by one way ANOVA with Dunnett’s post-hoc test. * P < 0.05, ** P < 0.01. 
C Quantification of TH+ PMNs after transfection with Foxo1 and/ or Foxo3 siRNA or NC and with addition of 
PBS for 24 h as experimental control.  
D Relative quantification of surviving TH+ PMNs after transfection with Foxo1 and/ or Foxo3 siRNA or NC 
and addition of 2 µM MPP
+
 for 24 h normalized to PBS treated cells (n = 5 independent cultures). Data are 
presented as mean ± SEM and were analyzed by one way ANOVA with Dunnett’s post-hoc test. * P < 0.05. 
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Supplemental tables 
Table S1 - Differential expression analysis small RNA sequencing.  
Differential expression analyses comparing miR expression levels between DIV 1 and DIV 5 (during  
development), the effect of GDNF-treatment at DIV 1 and the effect of GDNF-treatment at DIV 5 
(Corresponding to Fig 1). Separate excel file. 
 
Table S2 – Gene ontology (GO) and KEGG-pathway enrichment analyses for predicted miR-182-5p and 
miR-183-5p target genes (Corresponding to Fig 1). 
 
 
 
 
 
